Compass Therapeutics' Tovecimig Combination Cuts Progression or Death Risk 56% in Biliary Tract Cancer Trial

By Public Technologies
  • Compass Therapeutics published Phase 2/3 COMPANION-002 results for tovecimig in previously treated advanced biliary tract cancer in the Journal of Clinical Oncology.
  • The results are also being presented today at the 2026 European Society for Medical Oncology Congress in Madrid.
  • Tovecimig with paclitaxel improved tumor response and delayed disease progression compared with paclitaxel alone, meeting the study’s primary and key secondary goals.
  • No statistically significant overall survival benefit emerged; crossover to combination treatment complicated the analysis.
  • No new safety signals emerged, though severe adverse events and treatment discontinuations were more frequent with the combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240415PRIMZONEFULLFEED9852323) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.